Biotech and Pharma

Tesla drops after setting a record closing high, while Lennar tumbles following weak earnings for the home builder.

The decision comes less than two weeks after a committee of advisers to the agency, whom Robert F. Kennedy Jr. appointed this year, voted to change their decades-old guidance.

Shares of Tesla close on a record high.

Pfizer expects revenue and earnings to fall in 2026.

Baker Brothers Advisors has been buying up shares of companies in the biopharma and biotech space.

Americans without health insurance could be paying more than 10 times as much for the weight-loss drugs.

The company said some patients had dropped out of the trial because they felt they were losing too much weight.

Tom Hancock, a portfolio manager at GMO, favors companies that consistently earn a high return on capital and reinvest in the business.

What a SpaceX IPO could mean for Tesla shareholders, Pfizer pursuing next weight-loss drug in Chinese labs, more news to start your day.

Terns Pharmaceuticals shares jumped as much as 50% on news that cancer cell counts fell over 99% in nearly three-fourths of leukemia patients treated with the firm’s once-daily pill.

Big American drugmakers are hunting for novel weight loss drugs in the labs of China’s biotech industry, while U.S. authorities try to undercut the growing Chinese biotech sector.

The biopharma company is counting on KT-621 to treat patients with Type 2 inflammatory diseases.

Data from Structure Therapeutics and WAVE Life Sciences show that threats to the incumbents’ dominance are on the way.

RA Capital Management’s Peter Kolchinsky says the companies that survived the industry’s 2021 rout are thriving—and looking to make deals.

The drugmaker is testing its antipsychotic drug Cobenfy for the treatment of psychosis associated with Alzheimer’s disease.

Morgan Stanley upgrades shares of the medtech to Overweight from Equal Weight.

Janux posts what it called ‘positive trial data’ for its novel treatment in patients with late-stage prostate cancer.

Those four companies, culled from a list drawn up by KBW analyst Shreyank Gandhi, are among the largest not in the index.

The FDA’s top vaccine regulator outlines proposed changes to the vaccine evaluation process in an internal memo.

Investors will be weighing up how to shield their portfolios in case the rebound loses steam. These stocks look tempting.

Activists also report to the SEC on Acadia Healthcare, Butterly Network, National Energy Services Reunited, and Invivyd.

Zolgensma is only approved for infants with spinal muscular atrophy. Older people will be able to use a new version of the treatment, called Itvisma.

Shares, though, were punished Monday after the drug maker said its blockbuster obesity treatment Wegovy failed to slow Alzheimer’s.

The drugmaker says an oral version of Wegovy improved Alzheimer’s-related biomarkers, but didn’t delay the disease’s progression.